EC Clinical and Medical Case Reports

Clinical and epidemiological researches have examined the relationship between leptin and arterial stiffness, either in isolation or in conjunction with other adipokines in obese patients. The developed adipocytes of white subcutaneous adipose tissue are the primary producers of leptin. In the central nervous system, leptin plays a critical function in controlling energy expenditure and food intake. It lowers appetite and raises energy needs. However, hyperleptimenia, which is associated with higher levels of fat in obesity, suggests that there is a leptin resistant state [1].

1. Obradovic M., et al. “Leptin and obesity: Role and clinical implication”. Frontiers in Endocrinology (Lausanne) 12 (2021): 585887.
2. Ryan MJ., et al. “Vascular smooth muscle-specific deletion of the leptin receptor attenuates leptin-induced alterations in vascular relaxation”. American Journal of Physiology-Regulatory, Integrative and Comparative Physiology 10 (2016): R960-R967.
3. Poetsch MS., et al. “Role of leptin in cardiovascular diseases”. Frontiers in Endocrinology (Lausanne) 11 (2020): 354.
4. Raman P and Khanal S. “Leptin in atherosclerosis: focus on macrophages, endothelial and smooth muscle cells”. International Journal of Molecular Sciences 11 (2021): 5446.
5. López-Acosta O., et al. “Smooth muscle cells from a rat model of obesity and hyperleptinemia are partially resistant to leptin-induced reactive oxygen species generation”. Antioxidants (Basel)3 (2023): 728.
6. Su X., et al. “The important role of leptin in modulating the risk of dermatological diseases”. Frontiers in Immunology 11 (2021): 593564.
7. Kirichenko TV., et al. “The role of adipokines in inflammatory mechanisms of obesity”. International Journal of Molecular Sciences 23 (2022): 14982.
8. Kumar R., et al. “Association of leptin with obesity and insulin resistance”. Cureus 12 (2020): e12178.
9. Shariq OA and McKenzie TJ. “Obesity-related hypertension: a review of pathophysiology, management, and the role of metabolic surgery”. Gland Surgery 1 (2020): 80-93.
10. Jung MH and Ihm SH. “Obesity-related hypertension and chronic kidney disease: from evaluation to management”. Kidney Research and Clinical Practice 4 (2023): 431-444.
11. Aliyu M., et al. “Interleukin-6 cytokine: An overview of the immune regulation, immune dysregulation, and therapeutic approach”. International Immunopharmacology 111 (2022): 109130.
12. Kim M., et al. “Early involvement of peripherally derived monocytes in inflammation in an NMO-like mouse model”. Scientific Reports 1 (2024): 1177.
13. Luk C., et al. “Paracrine role of the endothelium in metabolic homeostasis in health and nutrient excess”. Frontiers in Cardiovascular Medicine 9 (2022): 882923.
14. Xu X., et al. “Transforming growth factor-β in stem cells and tissue homeostasis”. Bone Research 6 (2018): 2.
15. Meneses MJ., et al. “Paraoxonase-1 as a regulator of glucose and lipid homeostasis: impact on the onset and progression of metabolic disorders”. International Journal of Molecular Sciences 16 (2019): 4049.
16. Masenga SK., et al. “Mechanisms of oxidative stress in metabolic syndrome”. International Journal of Molecular Sciences 9 (2023): 7898.
17. Sun J., et al. “Fasting therapy contributes to the improvement of endothelial function and decline in vascular injury-related markers in overweight and obese individuals via activating autophagy of endothelial progenitor cells”. Evidence-Based Complementary and Alternative Medicine (2020): 3576030.
18. D'Elia L., et al. “Serum leptin is associated with increased pulse pressure and the development of arterial stiffening in adult men: results of an eight-year follow-up study”. Hypertension Research 11 (2021): 1444-1450.
19. Wu TJ., et al. “Serum leptin level is positively correlated with aortic stiffness in patients with type 2 diabetes mellitus”. Frontiers in Bioscience (Landmark Ed)6 (2023): 128.
20. Finelli C. “Intermittent fasting: a trend or an efficient method to lose weight?”. EC Clinical and Medical Case Reports 12 (2023): 01-04.